Compare MBUU & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBUU | LRMR |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.4M | 455.8M |
| IPO Year | 2013 | 2014 |
| Metric | MBUU | LRMR |
|---|---|---|
| Price | $28.79 | $3.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $32.20 | $16.50 |
| AVG Volume (30 Days) | 259.1K | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.74 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $807,561,000.00 | N/A |
| Revenue This Year | $2.14 | N/A |
| Revenue Next Year | $12.78 | $1,816.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.84 | $2.72 |
| 52 Week High | $39.65 | $6.42 |
| Indicator | MBUU | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 57.33 | 45.92 |
| Support Level | $27.00 | $3.12 |
| Resistance Level | $29.87 | $3.74 |
| Average True Range (ATR) | 1.25 | 0.28 |
| MACD | 0.11 | 0.04 |
| Stochastic Oscillator | 81.31 | 52.32 |
Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high-end offshore and outboard motorboats, in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Most recently, in 2026, it tied up with Saxdor Yachts, focused on adventure dayboats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.